Oxytocin high dose regimen for intrauterine fetal death

© Department for Health and Ageing, Government of South Australia. All rights reserved.

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

• The use of interpreter services where necessary,
• Advising consumers of their choice and ensuring informed consent is obtained,
• Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
• Documenting all care in accordance with mandatory and local requirements

Explanation of the aboriginal artwork:
The aboriginal artwork used symbolises the connection to country and the circle shape shows the strong relationships amongst families and the aboriginal culture. The horse shoe shape design shown in front of the generic statement symbolises a woman and those enclosing a smaller horse shoe shape depicts a pregnant woman. The smaller horse shoe shape in this instance represents the unborn child. The artwork shown before the specific statements within the document symbolises a footprint and demonstrates the need to move forward together in unison.

Purpose and Scope of Perinatal Practice Guideline
The purpose of this guideline is to provide clinicians with information on high dose oxytocin regimen, specifically for use with intrauterine fetal death. It details medication information, dosage, administration and observations.
Table I: Oxytocin high dose infusion regimen for IUFD

<table>
<thead>
<tr>
<th>Initial rate</th>
<th>increments</th>
<th>maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 mL / hour (10 mU / min)</td>
<td>Every 30 minutes (until 3-4 moderate to strong contractions in 10 minutes are achieved)</td>
<td>60 mL / hour (100 mU / min)</td>
</tr>
</tbody>
</table>

Draw up 100 units (10 ampoules) oxytocin and add to 1 litre of either Hartmann’s or 0.9 % sodium chloride solution
Summary of Practice Recommendations
The oxytocin high dose regimen for IUFD is used at < 34 weeks of gestation or when other methods of induction have failed. Uterine scar, grand multiparity and a live viable fetus are contraindications for use. Observe for signs and symptoms of water intoxication.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IUFD</td>
<td>Intrauterine fetal death</td>
</tr>
<tr>
<td>mU</td>
<td>Milliunit(s)</td>
</tr>
<tr>
<td>min</td>
<td>Minute</td>
</tr>
<tr>
<td>mL</td>
<td>Millilitre(s)</td>
</tr>
</tbody>
</table>
Oxytocin high dose regimen for intrauterine fetal death

Introduction

> Oxytocin (Syntocinon®) is synthetic oxytocin, a nonapeptide hormone normally released by the posterior lobe of the pituitary. Being wholly synthetic, it does not contain vasopressin and has a constant and reliable effect.\(^1\)
> Oxytocin stimulates the smooth muscle of the uterus, producing rhythmic contractions. It also causes contraction of the myo-epithelial cells surrounding the mammary alveoli.\(^1\)
> Infusion rates ≥ 20 mU / min can decrease free water clearance by the kidney via interaction with the vasopressin receptor in the kidney, resulting in water intoxication.\(^2,3\)
> Because of low concentrations of oxytocin receptors, the effectiveness of oxytocin for inducing labour in the second trimester of pregnancy is generally poor.\(^2\)

Indications

> Oxytocin is used to initiate uterine contractions and to maintain labour until delivery of the fetus is achieved
> For induction of labour after intrauterine fetal death (IUFD), the conventional oxytocin regimen should be used if gestation is > 34 weeks (see in PPG, oxytocin: augmentation and induction of labour infusion regimens)
> The oxytocin high dose regimen for IUFD is used at < 34 weeks of gestation or when other methods of induction have failed
> It can also be used for genetic termination of pregnancy when other methods of induction have failed

Contraindications for a high dose regimen

> Uterine scar
> Grand multiparity
> Live viable fetus

Dosage and administration

> The oxytocin high dose infusion is run as a separate line piggy-backed into the main line
> Prepare a main line infusion of either Hartmann’s or 0.9 % sodium chloride (to keep vein open)
> Prepare a side line infusion of 100 units (10 ampoules) of oxytocin in either 1 litre of Hartmann’s or 0.9 % sodium chloride and follow administration regimen as per table below
> Aim for 3 to 4 moderate to strong contractions per 10 minutes
> Do not exceed an oxytocin infusion rate of 60 mL / hour (100 mU / min)
> Continue regimen until delivery of the fetus
> Active management of third stage with 5-10 units of intravenous oxytocin given slowly
Oxytocin high dose regimen for intrauterine fetal death

Observations

Assess the following

- Pulse and respirations and contractions every half hour while increasing intravenous oxytocin dosage
- Blood pressure, descent of presenting part, per vaginam loss every hour
- Temperature every 4 hours (every hour if febrile)
- Maintain fluid balance chart and restrict additional fluids if infusion rate exceeds 40 mL / hour
- Need for pain relief

Observe for symptoms and signs of water intoxication

- Headache, nausea, vomiting and abdominal pain
- Lethargy, drowsiness
- Low blood electrolyte concentration
- Urinary output
Oxytocin high dose regimen for intrauterine fetal death

References

Acknowledgements
The South Australian Perinatal Practice Guidelines gratefully acknowledge the contribution of clinicians and other stakeholders who participated throughout the guideline development process particularly:

Write Group Lead
Judy Coffey
Catherine Leggett

Write Group Members
SAPPG work group 2004-2014

SAPPG Management Group Members
Sonia Angus
Dr Kris Bascomb
Lyn Bastian
Elizabeth Bennett
Dr Feisal Chenia
John Coombas
A/Prof Rosalie Grivell
Dr Sue Kennedy-Andrews
Jackie Kitschke
Catherine Leggett
Dr Anupam Parange
Dr Andrew McPhee
Rebecca Smith
A/Prof John Svigos
Dr Laura Willington
Oxytocin high dose regimen for intrauterine fetal death

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: HealthCYWHSPerinatalProtocol@sa.gov.au
Endorsed by: SA Health Safety and Quality Strategic Governance Committee
Next review due: 19 December 2019
PDS reference: CG188
Policy history:
- Is this a new policy (V1)? N
- Does this policy amend or update an existing policy? Y
  - If so, which version? V4
- Does this policy replace another policy with a different title? N
  - If so, which policy (title)?

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 July 2018</td>
<td>V4.1</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Review date extended to 5 years following risk assessment. New template.</td>
</tr>
<tr>
<td>19 Dec 2014</td>
<td>V4</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Reviewed in line with scheduled review date</td>
</tr>
<tr>
<td>15 Jan 2013</td>
<td>V3</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Reviewed in line with scheduled review date</td>
</tr>
<tr>
<td>18 May 2010</td>
<td>V2</td>
<td>Maternal and Neonatal Clinical Network</td>
<td>Reviewed in line with scheduled review date</td>
</tr>
</tbody>
</table>